Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Cedilla Therapeutics has raised $25.0M in total funding. The most recent round was Series B. The last funding was announced in October 2021.
Cedilla Therapeutics's investors include RA Capital Management, Eli Lilly, Janus Henderson Investors, Third Rock Ventures, Casdin Capital.
Cedilla Therapeutics is headquartered in Cambridge, United States.
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Cedilla Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cedilla Therapeutics — Funding & Investors." VCBacked, October 25, 2021, https://www.vcbacked.co/company/cedilla-therapeutics. Accessed August 17, 2026.
VCBacked. (2021). Cedilla Therapeutics — Funding & Investors. Retrieved August 17, 2026, from https://www.vcbacked.co/company/cedilla-therapeutics
{{cite web |title=Cedilla Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/cedilla-therapeutics |website=VCBacked |access-date=August 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated